5. Prevnar 13

Pneumococcal vaccine
2015 sales: $6.02 billion
2020 sales projection: $6.9 billion

Far and away the world's top vaccine in 2015, Pfizer's ($PFE) pneumococcal disease blocker Prevnar 13 will continue to reign atop the vaccines world through 2020, EvaluatePharma predicts.

Since hitting the European market in December 2009 and the U.S. market shortly after in February 2010, Pfizer's megablockbuster vaccine has gained sales expansions through additional regulatory nods and a prequalification from the World Health Organization. In a major decision in August 2014, the Centers of Disease Control's Advisory Committee on Immunization Practices recommended the shot for adults aged 65 and older in the U.S., a move estimated to help the jab bring in an additional $2 billion sales per year.

And so far for Pfizer, sales increases in 2015 have supported those estimates. Pfizer's Prevnar franchise brought in $6.2 billion in 2015, a jump from $4.46 billion in 2014. In the U.S. last year, Prevnar 13 sales increased 102% to help the New York pharma's vaccines unit achieve a 44% gain. The increases are due to "continued strong uptake" in U.S. adults since the ACIP recommendation, company execs have said.

EvaluatePharma's analysts have predicted that Prevnar 13 will capture nearly 17% of the entire vaccines market in 2020.

To continue the success, Pfizer's vaccines head Albert Bourla has said that Prevnar 13 can count on the U.S. adult catch-up population to last into this year and next. Additionally, 4 million people a year will reach age 65 in the U.S., execs have explained, and Pfizer is working "country by country" to broaden the vaccine's reach in G7 nations, Bourla said.

"And there, of course, you have a huge cohort of probably substantially larger than the U.S., probably twice the size of the U.S. And that's going to take market development," Bourla said.

In Pfizer's 2016 guidance, executives have said they expect the vaccine to maintain the strong performance, but cautioned against expecting any sales increases.

Though Prevnar 13 has been a shining star in the pharma's vaccines unit, Pfizer has worked in the last year to diversify the group beyond the jab, looking to both M&A and internal development to broaden its offerings. -- Eric Sagonowsky (email | Twitter)

5. Prevnar 13